CRIS Current Research Information System

BON, ISABELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.360
AS - Asia 3.601
EU - Europa 2.694
AF - Africa 264
SA - Sud America 206
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 11.136
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.315
SG - Singapore 1.038
VN - Vietnam 1.017
CN - Cina 816
GB - Regno Unito 570
IT - Italia 449
SE - Svezia 443
DE - Germania 348
HK - Hong Kong 274
FR - Francia 186
IN - India 162
BR - Brasile 157
RU - Federazione Russa 137
IE - Irlanda 123
TG - Togo 110
NL - Olanda 102
UA - Ucraina 97
ZA - Sudafrica 56
JP - Giappone 51
EE - Estonia 45
FI - Finlandia 41
JO - Giordania 38
NG - Nigeria 35
BG - Bulgaria 33
TH - Thailandia 30
CI - Costa d'Avorio 29
BD - Bangladesh 24
BE - Belgio 24
PH - Filippine 24
CA - Canada 23
CH - Svizzera 20
ID - Indonesia 20
AR - Argentina 19
KR - Corea 17
AT - Austria 16
PL - Polonia 16
MX - Messico 14
ES - Italia 11
IQ - Iraq 11
SC - Seychelles 10
TW - Taiwan 10
IR - Iran 9
TR - Turchia 9
SA - Arabia Saudita 8
PK - Pakistan 7
PT - Portogallo 7
UZ - Uzbekistan 7
CL - Cile 6
EC - Ecuador 6
MY - Malesia 6
VE - Venezuela 6
AU - Australia 5
CO - Colombia 5
LB - Libano 5
PE - Perù 5
RO - Romania 5
CZ - Repubblica Ceca 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
CY - Cipro 3
EG - Egitto 3
EU - Europa 3
GR - Grecia 3
LV - Lettonia 3
MA - Marocco 3
BS - Bahamas 2
CG - Congo 2
DK - Danimarca 2
DZ - Algeria 2
ET - Etiopia 2
HN - Honduras 2
IL - Israele 2
KE - Kenya 2
KH - Cambogia 2
NZ - Nuova Zelanda 2
PY - Paraguay 2
SI - Slovenia 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BH - Bahrain 1
BJ - Benin 1
GI - Gibilterra 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
MD - Moldavia 1
MG - Madagascar 1
MS - Montserrat 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
RS - Serbia 1
RW - Ruanda 1
Totale 11.133
Salva come PNG Salva come JPEG
Città #
Singapore 739
Ashburn 493
Southend 484
Fairfield 395
Chandler 337
San Jose 263
Hong Kong 258
Ho Chi Minh City 239
Santa Clara 224
Hanoi 217
Woodbridge 209
Seattle 190
Wilmington 170
Houston 168
Ann Arbor 164
Dong Ket 148
Princeton 138
Cambridge 133
Beijing 125
Dublin 123
Lomé 110
Bologna 96
Boardman 95
Florence 72
Lauterbourg 66
Nanjing 59
Westminster 54
Jacksonville 52
Padova 49
Los Angeles 46
Berlin 45
Turin 40
Amman 38
Tokyo 38
Da Nang 36
New York 34
Abeokuta 33
Sofia 33
Munich 32
Jinan 31
Redondo Beach 31
Shenyang 30
Abidjan 29
Buffalo 29
Milan 27
San Diego 27
Helsinki 26
Redmond 26
Hefei 25
Brussels 24
Saint Petersburg 24
Council Bluffs 22
Guangzhou 22
Hebei 22
Dallas 21
Frankfurt am Main 21
Haiphong 21
Tianjin 21
Zhengzhou 19
Phoenix 18
Rome 17
São Paulo 17
Chicago 16
Dearborn 16
Des Moines 16
Bremen 15
Hangzhou 15
Nanchang 15
Shanghai 15
Changsha 14
Ningbo 14
The Dalles 14
Atlanta 13
Jiaxing 13
Nuremberg 13
Olalla 13
Bern 12
Falls Church 12
Jakarta 12
London 12
Bangkok 11
Falkenstein 11
Orem 11
Turku 11
Can Tho 10
Hải Dương 10
Mülheim 10
Taizhou 10
Toronto 10
Warsaw 10
Bühl 9
Haikou 9
Montreal 9
Shenzhen 9
Thái Nguyên 9
Wuhan 9
Yubileyny 9
Amsterdam 8
Paris 8
Quận Bình Thạnh 8
Totale 7.236
Salva come PNG Salva come JPEG
Nome #
Restriction Factors expression decreases in HIV-1 patients after cART 269
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia 265
Analysis of the effects of HIV-1 Tat on the survival and differentiation of vessel wall-derived mesenchymal stem cells 236
Acute onset myopericarditis as unusual presentation of primary HIV infection 236
Discordant resistance interpretations in multi-treated HIV-1 patients 234
Comparison of the Aptima HIV-1 Quant Dx Assay with the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 v2.0 Test for HIV-1 Viral Load Quantification in Plasma Samples from HIV-1-Infected Patients. 233
Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1 232
Conflicting interpretations of the prevalence of mutations associated with drug resistance in antiviral naive HIV-1 patients with acute and chronic infection 225
Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19 210
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral Therapy 205
HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients. 202
Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people 199
Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke 196
Dual raltegravir-darunavir/ritonavir combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy including a ritonavir-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors 191
Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures. 189
Effects of Antiretroviral Molecules on Survival and Gene Expression of an Osteoblast-like Cell Line 189
Antiretroviral molecules and cardiovascular diseases. 188
Impact of different antiretroviral strategies on total HIV-DNA level in virologically suppressed HIV-1 infected patients. 187
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures 185
Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection. 184
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 183
HIV-1 early and late diagnosis in the Emilia Romagna Region (Italy): A three year study 179
Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy. 179
Recent and long-lasting infections: the need for avidity testing in HIV-1 infected subjects. 177
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz 171
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control study. 171
Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. 170
HIV-1 Tat protein concomitantly down-regulates apical caspase-10 and up-regulates c-FLIP in lymphoid T cells: A potential molecular mechanism to escape TRAIL cytotoxicity 170
HIV and kidney: A dangerous liaison 167
No correlation between statin exposure and incident diabetes mellitus in HIV-1-infected patients receiving combination antiretroviral therapy 166
HIV-1 infection of a nurse from a newborn with an unknown HIV infection: a case report. 165
HIV-1 coreceptor usage in paired plasma RNA and proviral DNA from patients with acute and chronic infection never treated with antiretroviral therapy 165
Low avidity antibody: a reliable method to diagnose a recent HIV-1 infection. 164
HIV-related mechanisms in atherosclerosis and cardiovascular diseases. 163
Human T-lymphotropic virus type 1 (HTLV-1) prevalence and quantitative detection of DNA proviral load in individuals with indeterminate/positive serological results 162
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 161
Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns 158
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients 158
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 158
Durable viral suppression in an HIV-infected patient in the absence of antiretroviral therapy 154
HIV-1 gp120 impairs the differentiation and survival of cord blood CD34+ HPCs induced to the erythroid lineage. 154
V3 net charge: additional tool in HIV-1 tropism prediction 151
An HIV type 2 case series in Italy: A phylogenetic analysis 149
Prevalence of transmitted drug resistance mutations among newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy 145
Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia 143
Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. 141
Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy 139
Do the HIV-1 subtypes circulating in Italy resemble the Red Queen running in Carroll's novel? 136
Fulminant type 1 autoimmune hepatitis in a recently diagnosed celiac disease patient. 135
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. 131
Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy 129
Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. 127
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group. 123
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: Results from the DIVA study group 123
Significant association between statin-associated myalgia and Vitamin D deficiency among treated HIV-infected patients 123
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study) 123
Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir 123
Improving counterfactual reasoning with kernelised dynamic mixing models 117
HBsAg seroreversion in HBsAg-negative/HBcAb-positive patients with HIV infection treated with direct-acting antivirals for HCV: A retrospective study 116
COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection. 114
null 113
Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy 110
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients 104
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome. 102
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir 101
Hepatitis A virus in a medical setting in Madagascar: a lesson for public health 97
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine. 94
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir 92
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir. 83
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir 78
Improvement in insulin sensitivity after switching from an integrase inhibitor-based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain. 69
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. 50
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia. 43
Totale 11.374
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.935
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.935
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021309 0 0 0 0 0 0 0 0 0 44 37 228
2021/20221.375 71 75 66 147 103 62 31 107 57 230 252 174
2022/20231.577 142 231 59 193 138 96 38 100 271 57 171 81
2023/2024404 25 66 39 52 31 81 19 24 9 29 21 8
2024/20251.602 72 247 133 129 295 90 73 40 19 129 55 320
2025/20263.468 335 320 260 250 391 222 437 207 815 231 0 0
Totale 11.374